| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-d...
 
																	Needham analyst Gil Blum reiterates Generation Bio (NASDAQ:GBIO) with a Buy and maintains $15 price target.
 
																	
 
																	Wedbush analyst David Nierengarten downgrades Generation Bio (NASDAQ:GBIO) from Outperform to Neutral and maintains the pric...
 
																	
 
																	Shares of Sapiens International Corporation NV (NASDAQ:SPNS) rose sharply in pre-market trading after it announced on Wednesday...
 
																	Generation Bio (NASDAQ:GBIO) reported quarterly losses of $(3.12) per share which missed the analyst consensus estimate of $(2....
 
																	
